Tags

Type your tag names separated by a space and hit enter

Unravelling the interaction mechanism between clioquinol and bovine serum albumin by multi-spectroscopic and molecular docking approaches.

Abstract

Clioquinol has recently been proposed for the treatment of Alzheimer's disease. It is able to diminish β-amyloid protein aggregation and to restore cognition of Alzheimer's mice. However, its therapeutic benefits for Alzheimer's disease in human remain controversy and need further confirmation. Herein, we have explored the interaction mechanism of clioquinol toward bovine serum albumin (BSA) by means of multi-spectroscopic and docking simulation approaches. Clioquinol interacts with BSA by a combined mechanism of static and dynamic processes. Application of the Hill's equation to fluorescence quenching experiment revealed that the binding constant of the BSA-clioquinol complex is extremely high at 108 M-1 level. Competitive displacement and docking analysis consistently suggested that there are the multiple binding modes of clioquinol toward BSA. Competitive binding study showed that clioquinol shares the binding sites with ibuprofen and digitoxin on albumin, referring to be site II and site III binding compounds. Besides, partial binding in site I was also observed. Docking simulation confirmed that clioquinol favors to bind in site I, site II, site III, fatty acid binding site 5, and the protein cleft between subdomain IB and IIIB of the BSA. Due to its small size and electric dipole property, clioquinol may easily fit in multiple pockets of the BSA. Our finding suggests the potential role of BSA as a clioquinol carrier in the vascular system. Nonetheless, clioquinol-induced BSA aggregation has been observed by the three-dimensional fluorescence technique. This phenomenon may not only impair the BSA, but may also affect other endogenous proteins, which eventually causes adverse effects to human. Therefore, the redesigned or modified molecular structure of clioquinol may reduce its toxicity and improve its bioavailability.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Nakhonpathom 73170, Thailand. Electronic address: tanawut.tan@mahidol.ac.th.

    ,

    Center for Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhonpathom 73170, Thailand.

    Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhonpathom 73170, Thailand.

    Source

    MeSH

    Animals
    Binding Sites
    Cattle
    Clioquinol
    Molecular Docking Simulation
    Protein Aggregates
    Protein Binding
    Serum Albumin, Bovine
    Thermodynamics

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    30865872

    Citation

    Tantimongcolwat, Tanawut, et al. "Unravelling the Interaction Mechanism Between Clioquinol and Bovine Serum Albumin By Multi-spectroscopic and Molecular Docking Approaches." Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, vol. 216, 2019, pp. 25-34.
    Tantimongcolwat T, Prachayasittikul S, Prachayasittikul V. Unravelling the interaction mechanism between clioquinol and bovine serum albumin by multi-spectroscopic and molecular docking approaches. Spectrochim Acta A Mol Biomol Spectrosc. 2019;216:25-34.
    Tantimongcolwat, T., Prachayasittikul, S., & Prachayasittikul, V. (2019). Unravelling the interaction mechanism between clioquinol and bovine serum albumin by multi-spectroscopic and molecular docking approaches. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 216, pp. 25-34. doi:10.1016/j.saa.2019.03.004.
    Tantimongcolwat T, Prachayasittikul S, Prachayasittikul V. Unravelling the Interaction Mechanism Between Clioquinol and Bovine Serum Albumin By Multi-spectroscopic and Molecular Docking Approaches. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Jun 5;216:25-34. PubMed PMID: 30865872.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Unravelling the interaction mechanism between clioquinol and bovine serum albumin by multi-spectroscopic and molecular docking approaches. AU - Tantimongcolwat,Tanawut, AU - Prachayasittikul,Supaluk, AU - Prachayasittikul,Virapong, Y1 - 2019/03/04/ PY - 2018/09/30/received PY - 2019/03/02/revised PY - 2019/03/03/accepted PY - 2019/3/14/pubmed PY - 2019/6/25/medline PY - 2019/3/14/entrez KW - Anti-Alzheimer KW - Bovine serum albumin KW - Clioquinol KW - Fluorescence quenching KW - Multi-spectral analysis SP - 25 EP - 34 JF - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy JO - Spectrochim Acta A Mol Biomol Spectrosc VL - 216 N2 - Clioquinol has recently been proposed for the treatment of Alzheimer's disease. It is able to diminish β-amyloid protein aggregation and to restore cognition of Alzheimer's mice. However, its therapeutic benefits for Alzheimer's disease in human remain controversy and need further confirmation. Herein, we have explored the interaction mechanism of clioquinol toward bovine serum albumin (BSA) by means of multi-spectroscopic and docking simulation approaches. Clioquinol interacts with BSA by a combined mechanism of static and dynamic processes. Application of the Hill's equation to fluorescence quenching experiment revealed that the binding constant of the BSA-clioquinol complex is extremely high at 108 M-1 level. Competitive displacement and docking analysis consistently suggested that there are the multiple binding modes of clioquinol toward BSA. Competitive binding study showed that clioquinol shares the binding sites with ibuprofen and digitoxin on albumin, referring to be site II and site III binding compounds. Besides, partial binding in site I was also observed. Docking simulation confirmed that clioquinol favors to bind in site I, site II, site III, fatty acid binding site 5, and the protein cleft between subdomain IB and IIIB of the BSA. Due to its small size and electric dipole property, clioquinol may easily fit in multiple pockets of the BSA. Our finding suggests the potential role of BSA as a clioquinol carrier in the vascular system. Nonetheless, clioquinol-induced BSA aggregation has been observed by the three-dimensional fluorescence technique. This phenomenon may not only impair the BSA, but may also affect other endogenous proteins, which eventually causes adverse effects to human. Therefore, the redesigned or modified molecular structure of clioquinol may reduce its toxicity and improve its bioavailability. SN - 1873-3557 UR - https://www.unboundmedicine.com/medline/citation/30865872/Unravelling_the_interaction_mechanism_between_clioquinol_and_bovine_serum_albumin_by_multi-spectroscopic_and_molecular_docking_approaches L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-1425(19)30236-7 DB - PRIME DP - Unbound Medicine ER -